Lyka Labs

Who are the top shareholders of the Lyka Labs?

The top shareholders of Lyka Labs primarily include promoters, with Ipca Laboratories Limited as the largest shareholder at 40.98%. Other notable shareholders are Thermo Capital Private Limited (1.55%) and individual investors (31.18%), along with minimal stakes from mutual funds and foreign institutional investors.

The top shareholders of Lyka Labs include several key players. The majority of the shares are held by promoters, with Ipca Laboratories Limited being the largest individual shareholder, holding 40.98%. Other notable shareholders include Thermo Capital Private Limited, which holds 1.55%, and individual investors collectively owning 31.18%. Additionally, there are four mutual fund schemes with a very small stake of 0.01% and five foreign institutional investors (FIIs) holding 0.23%. Overall, the promoter group plays a significant role in the ownership structure of Lyka Labs.

Who are in the management team of Lyka Labs?

As of March 2023, the management team of Lyka Labs includes Kunal Narendra Gandhi (Chairman & MD & CEO), Yogesh B Shah (Executive Director & CFO), and several independent and non-executive directors, overseeing the company's operations and strategy.

As of March 2023, the management team of Lyka Labs includes the following members:<BR><BR>1. Kunal Narendra Gandhi - Chairman & MD & CEO<BR>2. Sandeep P Parikh - Non-Executive & Independent Director<BR>3. Yogesh B Shah - Executive Director & CFO<BR>4. Dhara P. Shah - Non-Executive & Independent Director<BR>5. Kishore P Shah - Company Secretary & Compliance Officer<BR>6. Babulal Jain - Independent Director<BR>7. Prashant Godha - Director<BR>8. Shashil Mendonsa - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Lyka Labs do?

Lyka Labs Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on manufacturing formulations, bulk drugs, and healthcare products. As of March 2025, it reported net sales of 33 Cr and a net profit of 2 Cr, with a market cap of Rs 417 Cr.

Overview:<BR>Lyka Labs Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company, focusing on manufacturing formulations, bulk drugs, and a range of healthcare products.<BR><BR>History:<BR>Lyka Labs Ltd was incorporated in April 1983, initially manufacturing formulations and later amalgamating with Lyphin Chemicals Pvt Ltd. The company has diversified over the years, including marketing medical and diagnostic equipment. The latest reported quarterly results show net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 33 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 417 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 50.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.37 <BR>Return on Equity: 7.99% <BR>Price to Book: 3.99 <BR><BR>Contact Details:<BR>Address: 4801/B & 4802/A, GIDC Industrial Estate Ankleshwar Gujarat : 393002 <BR>Tel: 91-02646-221422/220549 <BR>Email: companysecretary@lykalabs.com <BR>Website: http://www.lykalabs.com

Has Lyka Labs declared dividend?

No Dividend History Available

Who are the peers of the Lyka Labs?

Lyka Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab, Everest Organics, SMS Lifesciences, and Zenotech Lab. Lyka Labs has average growth and below average capital structure, with a 1-year return of 11.65%, higher than Cipla's but lower than Everest Organics' 252.60%.

Peers: The peers of Lyka Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab., Everest Organics, SMS Lifesciences, and Zenotech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Lyka Labs, while Average management risk is found at Everest Organics, SMS Lifesciences, and Zenotech Lab. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is noted at Lyka Labs, and Below Average growth is seen at Divi's Lab., Torrent Pharma, Brooks Lab., Everest Organics, SMS Lifesciences, and Zenotech Lab. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted at Lyka Labs, Brooks Lab., Everest Organics, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 252.60%, while the peer with the lowest is Cipla at 0.84%. Lyka Labs has a 1-year return of 11.65%, which is higher than Cipla's but lower than Everest Organics'. Additionally, peers with negative six-month returns include Lyka Labs and Zenotech Lab.

What is the technical trend for Lyka Labs?

As of June 2, 2025, Lyka Labs shows a mildly bearish trend, supported by daily moving averages and a bearish monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 2 June 2025, the technical trend for Lyka Labs has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are also mildly bearish, reinforcing the bearish sentiment. Bollinger Bands on the monthly chart show a bearish trend, while both the KST and Dow Theory indicate no clear trend on a monthly basis. Overall, the current stance is mildly bearish, with the daily moving averages and monthly MACD being key indicators driving this outlook.

How big is Lyka Labs?

As of 24th July, Lyka Labs Ltd has a market capitalization of 401.00 Cr and reported net sales of 138.50 Cr and a net profit of 8.27 Cr over the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Lyka Labs Ltd has a market capitalization of 401.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 138.50 Cr, while the sum of Net Profit for the same period is 8.27 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 103.55 Cr and Total Assets valued at 176.21 Cr.

How has been the historical performance of Lyka Labs?

Lyka Labs has shown fluctuating historical performance, with net sales increasing from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, while total operating income peaked at 194.08 Cr in Mar'22 before declining. Despite rising costs and low cash flow, the company improved profitability, achieving a profit after tax of 7.93 Cr in Mar'25, recovering from previous losses.

Answer:<BR>The historical performance of Lyka Labs shows a fluctuating trajectory over the years, with notable improvements in recent periods.<BR><BR>Breakdown:<BR>Lyka Labs' net sales increased from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, reflecting a positive growth trend. However, the total operating income peaked at 194.08 Cr in Mar'22 before declining to 138.50 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 76.23 Cr in Mar'23 to 120.56 Cr in Mar'25, indicating rising costs. Operating profit (PBDIT) showed volatility, with a high of 103.24 Cr in Mar'22, dropping to 20.17 Cr in Mar'25. Profit before tax improved to 11.12 Cr in Mar'25 from a loss of 13.23 Cr in Mar'23, while profit after tax also turned positive at 7.93 Cr in Mar'25, recovering from losses in previous years. The company's total assets increased to 176.21 Cr in Mar'25, up from 151.52 Cr in Mar'23, and total liabilities also rose to 176.21 Cr in Mar'25. Cash flow from operating activities remained low at 1.00 Cr in Mar'25, with a net cash outflow of 4.00 Cr. Overall, while Lyka Labs has shown signs of recovery in profitability and sales, it continues to face challenges with rising costs and cash flow management.

Is Lyka Labs overvalued or undervalued?

As of November 13, 2025, Lyka Labs is considered overvalued with a high PE ratio of 156.53 and a significant decline in performance, contrasting with its peers, which have more attractive valuations and growth expectations.

As of 13 November 2025, Lyka Labs has moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company is currently considered overvalued based on its high PE ratio of 156.53, an EV to EBIT of 119.79, and a Price to Book Value of 3.16. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Lyka Labs' PE ratio significantly exceeds that of Cipla, which stands at 22.65, and Dr. Reddy's Labs at 17.86, both of which are classified as attractive. Additionally, while Lyka Labs has a PEG ratio of 0.00, indicating no growth expectations, its peers like Sun Pharma and Divi's Lab are categorized as expensive with PEG ratios of 11.96 and 1.99, respectively. The recent performance of Lyka Labs shows a substantial decline, with a year-to-date return of -43.61%, contrasting sharply with the Sensex's positive return of 8.11% during the same period, further reinforcing the overvaluation narrative.

When is the next results date for Lyka Labs Ltd?

The next results date for Lyka Labs Ltd is 29 January 2026.

The next results date for Lyka Labs Ltd is scheduled for 29 January 2026.

Are Lyka Labs Ltd latest results good or bad?

Lyka Labs Ltd's latest Q2 FY26 results are poor, showing a net loss of ₹3.36 crores compared to a profit in the previous quarter, alongside a significant decline in operating margins and year-on-year revenue drop. Investors should be cautious due to the company's operational weaknesses and high valuation relative to its financial health.

Lyka Labs Ltd's latest results for Q2 FY26 indicate a troubling performance overall. The company reported a net loss of ₹3.36 crores, a significant decline from a profit of ₹0.93 crores in the previous quarter, marking a staggering 461.29% drop quarter-on-quarter and a 260% decline year-on-year. This loss is compounded by a collapse in operating margins, which fell to -6.93% from a positive 11.17% in Q1 FY26.<BR><BR>While revenue showed a slight sequential improvement of 10.99% to ₹36.66 crores, this still represents a year-on-year decline of 10.93%. The operational challenges are evident, with employee costs rising sharply, contributing to the negative operating profit before depreciation, interest, tax, and other income.<BR><BR>Overall, the financial metrics reflect significant operational weaknesses and a lack of institutional confidence, as evidenced by minimal institutional holdings. The company's high P/E ratio of 126.96x, compared to the sector average of 33x, further highlights the disconnect between its valuation and its current financial health.<BR><BR>Given these factors, the results can be characterized as quite poor, raising serious concerns about the company's sustainability and future prospects. Investors are advised to approach with caution, as the outlook appears bleak.

Should I buy, sell or hold Lyka Labs Ltd?

Which are the latest news on Lyka Labs?

Why is Lyka Labs Ltd falling/rising?

As of 03-Feb, Lyka Labs Ltd's stock price is Rs 69.95, reflecting a 4.18% decrease. The stock has significantly underperformed the market, with a year-to-date decline of 7.96% and a troubling 50.84% drop over the past year.

As of 03-Feb, Lyka Labs Ltd's stock price is falling, currently at Rs 69.95, which reflects a decrease of Rs 3.05 or 4.18%. The stock has underperformed significantly compared to the broader market, with a 1-week decline of 5.19% while the Sensex has gained 2.30%. Over the past month, the stock has dropped by 13.95%, contrasting with a slight decline of 2.36% in the Sensex. Year-to-date, Lyka Labs has seen a decrease of 7.96%, while the Sensex is down only 1.74%. <BR><BR>The stock's performance over the past year is particularly concerning, with a decline of 50.84% compared to a gain of 8.49% in the Sensex. Additionally, the stock is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Today, the stock opened with a gain of 9.45%, reaching an intraday high of Rs 79.9, but quickly fell to a low of Rs 69.85, showing high volatility with an intraday fluctuation of 12.57%. It is also close to its 52-week low, just 1.97% away from Rs 68.57. Despite a rise in delivery volume, which increased by 75.3% compared to the 5-day average, the overall performance today has underperformed the sector by 6.97%. This combination of factors contributes to the stock's current downward trajectory.